# Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

> **NCT01531998** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Siltuximab
- **DRUG:** Dexamethasone
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT01531998
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531998, "Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01531998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*